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Abstract
Biochemical analysis of the retinoblastoma protein's function has received considerable attention
since it was cloned just over 20 years ago. During this time pRB has emerged as a key regulator of
the cell division cycle and its ability to block proliferation is disrupted in the vast majority of human
cancers. Much has been learned about the regulation of E2F transcription factors by pRB in the cell
cycle. However, many questions remain unresolved and researchers continue to explore this
multifunctional protein. In particular, understanding how its biochemical functions contribute to its
role as a tumor suppressor remains to be determined. Since pRB has been shown to function as an
adaptor molecule that links different proteins together, or to particular promoters, analyzing pRB
by disrupting individual protein interactions holds tremendous promise in unraveling the intricacies
of its function. Recently, crystal structures have reported how pRB interacts with some of its
molecular partners. This information has created the possibility of rationally separating pRB
functions by studying mutants that disrupt individual binding sites. This review will focus on
literature that investigates pRB by isolating functions based on binding sites within the pocket
domain. This article will also discuss the prospects for using this approach to further explore the
unknown functions of pRB.
Background
The retinoblastoma susceptibility gene (RB-1) was the first
tumor suppressor gene to be cloned [1]. Since that time its
encoded protein (pRB) has emerged as a key regulator of
cell cycle entry and appears to be one of the most frequent
targets for inactivation in human cancer [2-5]. The retino-
blastoma protein is most frequently inactivated in cancer
by the negative regulatory activity of cyclin dependent
kinases [6]. Only in small cell lung carcinoma [7] and
retinoblastoma [8] is the RB-1 gene a frequent target for
direct mutation. Loss of heterozygosity at the RB-1 locus
has been reported in many different sporadic cancers, sug-
gesting that it is directly mutated outside of the lung and
retina, but on a less frequent basis [9]. Based on pRB's
prominent and ubiquitous role in cancer many investiga-
tors have focused their efforts on trying to determine its
biochemical function. A fundamental component to this
type of investigation is the evaluation of mutant alleles to
determine which aspects of cell physiology require pRB.
Ideally the analysis of very specific mutants will determine
which protein interactions account for how pRB func-
tions. This review will focus on the efforts that have been
made to rationally separate different aspects of pRB's
function in proliferative control and cancer.
Given that the focus of this review is on the dissection of
pRB function, some reports will inevitably be omitted
because they lack a structural component. By no means is
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this is meant to diminish their validity, it is hoped that all
aspects of pRB function will eventually fit into a frame-
work of defined protein interactions, unfortunately not all
are at this stage. In general terms, pRB has an established
role in mediating a G1 arrest in development and in
response to many growth regulatory signals [5]. Some
examples are DNA damage [10], or growth inhibiting
cytokines such as TGF-β [11]. In addition, pRB plays a key
role in the permanent cell cycle exit of differentiating cells
and this has been demonstrated both in cell culture and in
vivo using gene targeted mice [12,13]. The Retinoblastoma
protein plays an essential function in permanent cell cycle
arrest and differentiation of adipocytes [14], myotubes
[15], osteoblasts [16], and neurons [17]. In mechanistic
terms, much of pRB's ability to control the cell cycle has
been linked to its ability to regulate transcription [4,18].
The RB protein binds to E2F transcription factors and
blocks their ability to induce transcription of genes that
are needed to advance the cell cycle. In turn, once pRB is
brought to a promoter by an E2F it can recruit chromatin
remodeling proteins such as histone methyltransferases
[19], DNA methyltransferases [20], histone deacetylases
[21,22], and helicases [23] among others to further
repress transcription [24]. Stimulation of cell cycle entry
results in phosphorylation of pRB by cyclin/Cdk com-
plexes and causes the release of E2Fs and chromatin regu-
lators at the G1 to S-phase transition (Figure 1).
Beyond the simple model elaborated in Figure 1 where
pRB represses transcription in G1 to control S-phase entry,
it should be noted that recent work on pRB to validate this
mechanism is not without its controversies. However, one
common theme to pRB function is that it works as an
adaptor protein that can nucleate complexes containing
multiple interacting partners. For this reason, understand-
ing the consequence of the loss of one type of pRB inter-
action in isolation holds enormous promise to
characterizing how pRB works in controlling prolifera-
tion, or other functions, that make it a tumor suppressor.
Nature's bounty; using tumor-derived mutations 
in RB-1 to guide functional analysis
Before describing what has been learned from studying
pRB through a structure-function approach it is worth
understanding what mutant resources are available. For
example, oncogenic mutations in Ras are clustered at
codons 12 and 61 and these mutants have revealed the
importance of the GTP bound state [25]. This insight was
made possible by the fact that oncogenic mutations dis-
cretely cripple intrinsic GTP hydrolysis while leaving
interactions with downstream effectors intact. Generation
of mutations such as the S17N substitution has created a
dominant negative form of Ras whose over expression
blocks endogenous Ras signaling [26]. At this point there
are no known cancer causing mutations in RB-1 that offer
discrete separation of activities. Much of the effort to dis-
sect pRB function using cancer causing alleles has come
from mutations found in retinoblastoma families with
partially-penetrant inheritance [27-30], particularly the
R661W substitution (Figure 2). However, these alleles
encode proteins that contain multiple interaction defects.
Furthermore, there has been relatively limited use of gain-
of-function and dominant negative alleles of RB-1 to help
clarify its function despite efforts to develop these rea-
gents [31-35]. Instead, a number of tumor derived RB-1
mutants have actually emerged as excellent negative con-
trols!
In addition to Ras, another relevant comparison of muta-
tions is with p53. The TP53 gene is the most frequently
mutated gene in cancer [36]. Cataloguing hundreds of
tumor derived missense changes has been invaluable, as it
has revealed the importance of the DNA binding domain
in p53 tumor suppressor function. Some of these alleles
have also turned out to have dominant negative activity.
At present the vast majority of mutations found in retino-
blastoma patients are deletions or nonsense changes, sug-
gesting that these are null alleles [8,37]. There are 35
known cancer causing missense mutations in RB-1 from
retinoblastoma patients and most of these alleles have
only been reported once [37]. Taken together, this sug-
gests that the paucity of partially defective RB-1 mutants
has prevented the type of analysis of pRB that has played
a crucial role in understanding other oncogenes and
tumor suppressors. In short, nature has not been very gen-
erous in providing mutations to aid in analyzing the
mechanism of pRB function.
Transcriptional control of the cell cycle by pRB Figure 1
Transcriptional control of the cell cycle by pRB. In G1 
pRB is bound to E2Fs and masks their ability to activate tran-
scription. In turn, pRB can recruit a number of chromatin 
remodeling factors that can further inhibit the initiation of 
transcription. Mitogen signaling then activates cyclin/Cdk 
complexes that phosphorylate pRB in late G1 and early S-
phase leading to the disassembly of this complex and the acti-
vation of transcription of genes needed for progression 
through S-phase.
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Cut and paste, elucidating the domain structure 
of pRB
The retinoblastoma protein does not possess any com-
monly recognized DNA binding or protein interaction
domains, although crystallographic data demonstrates
that pRB contains two cyclin-folds and it has similarity to
other proteins with this structure [38,39]. Our present
knowledge of the domain structure of pRB has been deter-
mined by deletion mapping. These efforts have defined
the large and small 'pocket' domains (Figure 2). The
'small pocket' was initially identified as the minimal frag-
ment of pRB that can interact with viral proteins like SV40
TAg, HPV E7, and adenovirus E1A [40-42]. Crystal struc-
ture data indicates that the A and B halves of the small
pocket each represent a single cyclin fold and they interact
to form a dumbbell shaped globular domain [38]. Exper-
iments designed to define the minimal growth-suppress-
ing domain identified a slightly bigger piece of pRB that is
called the 'large pocket' [43]. The large pocket is also capa-
ble of complementing pRB's tumor suppressor activity in
vivo when expressed in place of the full-length protein
[44]. In addition, the cancer-causing missense mutations
in RB-1 that have been described are found mostly within
the large pocket and this has focused efforts most inten-
sively on this domain. Puzzlingly, there are two other pro-
teins in the RB-family called p107 and p130 that have
extensive similarities to pRB, particularly within the small
pocket [45,46]. Despite this similarity, there is little exper-
imental evidence to suggest these proteins have tumor
suppressive functions on their own as p107-/-;p130+/- and
p107+/-;p130-/- mice are not tumor prone [45]. This has fur-
ther focused the question on what does the pRB pocket
domain do that p107 and p130 can't do?
Dissection of interactions and separating functions within
the large pocket domain has been one of the rate limiting
steps to advancing our understanding of pRB by a struc-
ture-function approach. Initially, efforts to mutagenize
pRB were guided by sequence conservation and these have
lead to a number of insightful reports that separate differ-
ent aspects of pRB function [47-49]. However, crystal
structures of the pRB small pocket have revealed that
many of the most conserved amino acids are buried and
this suggests why some of these mutants have partial loss
of function for multiple interaction types [38]. Genera-
tion of synthetic mutant alleles of RB-1 that seek to create
discrete defects have been greatly aided by the crystal
structure of the small pocket. This has provided a detailed
description of which amino acids are on the surface of this
domain. Furthermore, recent co-crystal structures contain-
ing pRB and pieces of E2Fs have further indicated the sites
of important protein-protein interactions within the large
pocket region [50-52]. The use of this information to gen-
erate mutations and guide experimentation into the
mechanism of pRB function will hopefully pave the way
for a more rational understanding of how pRB controls
cell proliferation and suppresses cancer development.
The perspective that is presented above is meant to
emphasize that our mechanistic understanding of pRB is
still in its infancy because we are only now developing the
tools to discover how pRB works, or to definitively test
many of the long-standing models of its function. To fur-
ther emphasize the importance of mapping and disrupt-
ing individual protein-protein interaction sites in
mechanistic studies of pRB, the ensuing sections of this
review will be organized around individual protein-pro-
tein interaction sites or activities mediated by the large
pocket domain. To truly focus this review on structure-
function analysis of pRB, the work that is discussed will
highlight reports that attempt to dissect function within
the large pocket domain, and not merely demonstrate its
involvement. In this way the goal is not only to discuss
recent work, but also to present it from a viewpoint that
will reveal important gaps in our mechanistic knowledge
of pRB by attempting to describe its function as a sum of
a few discrete parts.
Regulation of E2F transcription factors, is it the 
key to pRB function or just another in a long list?
E2F1 was one of the first pRB interacting proteins to be
identified [53,54]. It is now known that pRB interacts with
the first four members of the E2F family [55]. Each of
these E2Fs needs to partner with a DP subunit to stably
interact with pRB and to bind to E2F promoter elements
[4]. Each of E2Fs 1, 2, and 3 are potent stimulators of cell
Commonly used RB-1 mutations and pRB domain structure Figure 2
Commonly used RB-1 mutations and pRB domain 
structure. The open reading frame of pRB is shown along 
with the locations of the A and B parts of the pocket. 
Arrows indicate the positions and alterations found in com-
monly studied low penetrance and high penetrance mutant 
alleles. Below the open reading frame, structural regions of 
pRB are identified along with their approximate locations.
AB
Small Pocket
Large Pocket
1 928
N-terminus C-terminus
Partially functional
low penetrance
alleles:
Null alleles
commonly used as
negative controls: C706F del738-75(exon 22)
delN480 R661W C712R del829-88(exons 24 & 25)
Spacer
del703-37(exon 21)
del127-66(exon 4)
ABCell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
Page 4 of 15
(page number not for citation purposes)
cycle progression from G1 to S-phase and are referred to
as 'activator' E2Fs [18]. Direct interaction with pRB blocks
this activating function because pRB masks its activation
domain [56-60]. Over expression of activator E2Fs can
bypass pRB's growth suppressing activity [61]. Likewise,
ectopic proliferation in Rb deficient mouse embryos can
be suppressed by reducing E2F activity by crossing to
E2F1, 2, or 3 knock out strains [62-64]. For these reasons
this interaction is viewed as central to how pRB functions
in proliferative control and as a tumor suppressor gene.
From a structure-function perspective, investigating the
properties of pRB mutants that are deficient for E2F bind-
ing has tested the importance of this interaction. The data
that has emerged from these studies will be discussed
below and it shows that E2F regulation is necessary for a
maximal cell cycle arrest by pRB, but it also indicates that
pRB has other growth regulating functions.
Initial reports of the disruption of E2F regulation by pRB
used the low penetrance pRB allele, R661W. This mutant
protein is defective for binding to E2F transcription fac-
tors in in vitro binding assays [28,47], and endogenous
interactions have been evaluated in knock-in mice where
this protein shows a dramatic reduction in binding to all
activator E2Fs. In cell culture assays, this mutant retains
some activity in proliferative control even though tran-
scriptional regulation of E2Fs has been lost [47,65]. In
addition, Saos-2 cells that are derived from an osteosar-
coma are able to undergo aspects of bone differentiation
and senescence in response to R661W [47]. The func-
tional effects of the R661W mutation in a knock in mouse
model are similar [66]. These animals develop to a slightly
later stage of gestation than the knock out, despite show-
ing complete deregulation of E2F transcription and con-
trol of fibroblast proliferation. The authors offer a number
of carefully examined paradigms for differentiation in
erythrocyte and macrophage lineages that show R661W
retains at least partial activity. Thus, the R661W mutation
may have more defects than loss of E2F regulation, but it
still retains some of pRB's growth regulating activity.
Two reports describe the structure of the small pocket
bound to the pRB binding domain of an E2F [50,52].
These have provided molecular insight into this impor-
tant interaction. Substitution of amino acids that mediate
E2F and pRB interactions has revealed that clean removal
of this E2F binding site can eliminate transcriptional
repression of E2F reporters [67,68]. Similar to what has
been found with R661W, discrete loss of E2F binding to
pRB does not abrogate all proliferative control activity as
most models of pRB function (such as that pictured in Fig-
ure 1) have predicted [67,68].
If removing E2F binding does not eliminate G1-S regula-
tion by pRB, but only cripples it, what functions remain to
control the cell cycle? One candidate that has been pro-
posed to mediate pRB arrest that is distinct from E2F reg-
ulation is p27. Using mutants of pRB that have impaired
E2F binding, p27 levels were shown to be elevated during
senescence induction in Saos-2 cells [49]. More recently,
an insightful report by Ji et al. showed that cells induced
to express wild type pRB are capable of arresting in G1
before repression of E2F targets takes place [69]. These
authors further demonstrate that the immediate activity in
cell cycle arrest comes from the pRB C-terminus' ability to
interfere with Skp2 targeting p27 for degradation. The
R661W mutant retains this function, reconciling this
activity with previous observations of cell cycle regulation
by this mutant. These experiments establish a direct link
between pRB and the control of cyclin/Cdk activity that is
separate from transcriptional regulation of cyclin and Cdk
genes. A more detailed evaluation of the mechanism of
Skp2 regulation by pRB reveals that APCCdh1 and Skp2
simultaneously bind to pRB [70]. This interaction targets
Skp2 for degradation. Analysis of the interaction sites for
these molecules with pRB reveals that Skp2 contacts the C-
terminal region of pRB [69] and Cdh1 makes use of the
LXCXE binding cleft in combination with E2F contacts in
the large pocket [70]. Based on the similarity of contact
sites used by APC and Skp2 in degradation, and those by
E2F/pRB/chromatin regulating complexes, it appears that
pRB has two discrete cell cycle control mechanisms that
are mediated by similar regions of the large pocket (Figure
3). This implies that in G1 two separate populations of
pRB are engaged in distinct growth regulating mecha-
nisms.
In the process of removing E2F binding from pRB by
mutagenesis it was also determined that pRB retains the
Binding sites for E2Fs and other proliferative control activi- ties Figure 3
Binding sites for E2Fs and other proliferative control 
activities. The open reading frame of pRB is shown with 
locations of the A and B parts of the pocket. Regions of con-
tact that have been mapped for E2F transcription factors, 
chromatin regulators, and protein degradation machinery 
that are involved in controlling proliferation are diagramed.
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ability to bind to E2F1 using a separate interaction site
[67,68]. This E2F1 only, or 'Specific' binding site, is
located exclusively in the C-terminal portion of pRB [67].
Furthermore, apoptotic induction by E2F1 can be inhib-
ited by a pRB mutant that is deficient for binding to all
other E2Fs [67]. Mutation of the E2F1 'Specific' binding
site inhibits this activity even when the other E2F binding
site is present [71]. Chau et al. have shown that a pRB
mutant that is incapable of regulating cell cycle advance-
ment and is only capable of binding to E2F1, can inhibit
apoptosis induced by DNA damage [68]. This suggests
that E2F1 regulation may have a role in DNA damage sig-
naling independent of cell cycle regulation by pRB.
Recently, the C-terminus of pRB was co-crystallized with
fragments of E2F1 and DP1 [51]. This structure reveals the
molecular contacts between a well-conserved portion of
pRB that is not found in p107 or p130 and a region of
E2F1 that is different from the other E2F family members.
In addition, swap experiments exchanging the contact site
on E2F1 with the analogous region of E2F3 demonstrate
that this interaction is truly unique to E2F1 [71]. Mecha-
nistically, it remains to be determined how pRB uses this
interaction with E2F1, however, the identification of a
novel pRB-E2F interaction through structure-function
analysis reveals that there are new regulatory pathways
that have yet to be explored.
Much emphasis has been placed on the central role of
pRB-E2F interactions in cell cycle control. Remarkably,
experiments that investigate the requirement for these
interactions reveal that they are important, but alone can
not explain how pRB controls proliferation. Future work
will need to quantitatively define the contribution of
these non-E2F mechanisms of cell cycle control. The
R661W mutation suggests that non-E2F and E2F depend-
ent cell cycle control mechanisms can be separated, how-
ever the pleiotropic nature of this mutation leaves us
unsure how much each contributes. Alleles that discretely
remove each arrest mechanism alone, or both together,
will help answer how much each contributes to pRB's
overall function. More importantly, do E2F and Cdh1/
Skp2 interactions account for all activity in cell cycle con-
trol by pRB or are their even more mechanisms? It will
also be necessary to use model organisms to investigate
how much E2F regulation contributes to pRB's role as a
tumor suppressor compared with Cdh1/Skp2 or others.
This type of analysis will ultimately determine how cen-
tral E2F regulation really is to pRB's function or whether
our models of pRB-E2F regulation in cancer need to be
reconsidered.
From viral transformation to the histone code, 
the LXCXE binding cleft has something for 
everyone
As described above, the small pocket region of pRB was
initially mapped as the minimal domain capable of bind-
ing to Adenovirus E1A, SV40 TAg, and HPV E7 [40]. Eval-
uation of the transforming properties of these viral
oncogenes revealed that a peptide motif called LXCXE was
necessary for pRB binding and transformation [72-77].
The convergent evolution of these very different viruses
highlights the importance of RB family inactivation in
viral transformation. Molecular insight into this interac-
tion was revealed when the LXCXE motif was co-crystal-
lized with the small pocket of pRB [38,78]. Beyond
revealing the intermolecular contacts between the LXCXE
motif and the pRB small pocket, this work also revealed
that the contact site of the LXCXE motif on pRB is one of
the most well conserved structural features of pRB family
proteins [38] (Figure 4). This region of the pocket is often
called the LXCXE binding cleft. The conservation of
amino acids in the LXCXE binding cleft implies that pro-
pRB and the LXCXE motif Figure 4
pRB and the LXCXE motif. (A) A repressor complex 
composed of an E2F transcription factor, pRB, and a chroma-
tin regulator is shown in G1. The interaction between pRB 
and the chromatin regulator is mediated by the peptide 
sequence LXCXE on the chromatin remodeling factor and 
the LXCXE binding cleft on pRB. Viral proteins like TAg, E7, 
and E1A can disrupt this complex because they contain an 
LXCXE motif. Disruption of this pRB-containing complex can 
advance the cell cycle into S-phase. (B) The LXCXE binding 
cleft on pRB is a shallow groove formed between two paral-
lel helices. The amino acid sequence of these helices in 
human pRB is aligned to the analogous sequences from pRB-
family proteins from humans, corn, fruit flies, worms, and 
algae. Shaded amino acids are identical between all protein 
comparisons. The asterisk denotes amino acids whose side 
chains make direct contact with LXCXE in the crystal struc-
ture reported by Lee et al. [38].
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tein interactions mediated by it are a key component of
pRB's function.
Amino acid sequence conservation provides a straightfor-
ward rationale for studying the LXCXE binding cleft on
pRB. Unfortunately, understanding how pRB uses LXCXE
type interactions in proliferative control remains ill
defined. One reason is that there are 28 proteins that have
been reported to interact with pRB using an LXCXE motif
(Table 1), raising the question of whether all of these
interactions are necessary for proliferative control events
mediated by pRB, or whether some are needed for more
specialized functions. It is beyond the scope of this review
to discuss how each of these molecules is proposed to
partner with pRB, however, most cellular proteins that
possess an LXCXE motif are believed to work with pRB in
transcriptional regulation. Some of these proteins have an
enzymatic activity or other property that can modify chro-
matin structure, these include BRG1, Brm, DNMT1,
HDAC1 and 2, HP1, RBP2, RIZ1, and Suv39h1 [19-23,79-
83]. Others have no clear biochemical activities, but con-
tribute to repression of transcription in cell culture assays,
or are themselves known transcription factors. These
include CtIP, EID1, ELF1, HBP1, RBP1, and UBF [82-90].
It is difficult to generalize the other LXCXE motif proteins,
but they participate in functions as varied as DNA replica-
tion and apoptosis while many have no clearly defined
functions. Examination of Brm, RBP1, RBP2, and HBP1
irrespective of pRB has revealed roles for them in regulat-
ing proliferation or maintaining terminal differentiation
[91-94].
Given the broad possibilities for how pRB can use LXCXE
type interactions (because of the vast number of interact-
ing proteins that contain this motif), recent efforts have
focused on mutating the LXCXE binding site on pRB and
examining the defects caused by loss of all LXCXE interac-
tions with pRB. Surprisingly, the ability to control cell
proliferation remained largely intact in Saos-2 cell cycle
arrest assays [95-98]. However, in some assays of perma-
nent cell cycle arrest, mutations in this region of pRB were
shown to allow cell cycle re-entry [96,98]. Recently, the
generation of a knock-in mutant mouse strain has been
described in which the LXCXE binding site on pRB has
been disrupted [99]. These mice are viable, implying that
cell cycle exit and differentiation occurs normally during
development. It remains to be seen if there are prolifera-
tive control defects in these mice or if they are cancer
prone because of them. However, the defect that was high-
lighted in this report was genomic instability. Disruption
of pRB-LXCXE interactions caused defects in heterochro-
matin condensation due to diminished histone H4-K20
trimethylation. Chromosomal regions normally charac-
terized by this modification become fused causing errors
in mitosis. Thus, one in vivo manifestation of defective
LXCXE interactions is abnormal chromatin structure.
Another approach to identify proteins that cooperate with
pRB by contacting the LXCXE binding site has been to
purify pRB containing protein complexes. Isolation of the
fruit fly RBF proteins with a complex of other transcrip-
tional regulators has offered insight into the assembly of
a transcriptional repressor module called dREAM
[100,101]. Sequence comparisons have revealed that this
is an evolutionarily conserved complex whose compo-
nents are found in distantly related organisms including
humans, flies, and C. elegans. This complex of proteins
contains subunits that are dependent on the LXCXE bind-
ing cleft for interaction with pRB in in vitro binding exper-
iments [100]. The use of ChIP assays to identify target
promoters and RNAi to deplete individual members of
this complex has revealed that it functions to block tran-
scription of a vast number of developmentally regulated
genes and is also involved in controlling DNA synthesis in
Drosophila  oocytes [100-103]. Mutations in the LXCXE
binding cleft in knock-in mice would be expected to dis-
rupt assembly of this complex, so how can dREAM be
essential for regulating so many transcriptional targets
while the knock-in mice remain viable? A recent clue has
Table 1: Proteins that use an LXCXE interaction motif to bind to 
pRB
Protein Biochemical Functions References
AhR Aryl hydrocarbon receptor [158]
ASK1 Ser/Thr kinase [159]
Bog Unknown [160]
BRG1 ATP dependent helicase [161]
Brm ATP dependent helicase [110]
CtIP Transcriptional repressor [84]
Cyclin D1 kinase regulatory subunit [162]
Cyclin D2 kinase regulatory subunit [163]
Cyclin D3 kinase regulatory subunit [164]
DNA Pol delta DNA polymerase [165]
DNMT1 DNA methyltransferase [20]
EID-1 Unknown [85] [86]
ELF1 Transcription factor [87]
HBP1 Transcriptional repressor [88] [89]
HP1 trimethyl histone H3 binding protein [19]
HDAC1 histone demethylase [21] [22] [80]
HDAC2 histone deacetylase [81]
Hec1 Unknown [166]
Hsp75 Heat-shock protein [167]
p202 Unknown [168]
p204 DNA replication [169]
RFC p145 DNA replication [170]
RBP1 Chromatin remodeling/
transcriptional repression
[82]
RBP2 histone demethylase [82]
RIM Unknown [171]
RIZ methyltransferase [83] [172]
Suv39h1 methyltransferase [19]
UBF PolI transcription factor [90]Cell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
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come from the isolation of endogenous protein com-
plexes containing the p130 protein [104]. This work has
revealed that endogenous human dREAM components
only assemble with p130 and not other pocket proteins,
suggesting that human pRB differs from pocket proteins
found in lower eukaryotes because it does not participate
in the dREAM complex [104].
In summary, mice with an LXCXE binding cleft mutation
have defective chromatin structure and this is in agree-
ment with chromatin regulating enzymes using an LXCXE
motif to bind to pRB [99]. However, the lack of obvious
cell cycle phenotypes caused by disruption of LXCXE
interactions in cell culture and knock-in mice reveals that
there is not a universal requirement for them in all aspects
of pRB's proliferative control activity [95-99]. The investi-
gation of transcriptional repression mechanisms using
model organisms like C. elegans and Drosophila has pro-
vided tremendous insight into the RB family of proteins.
However, their RB gene families are slightly different in
that they do not possess an exact orthologue of human
pRB. Because of these differences, the dREAM complex
seems unlikely to be a key cellular partner of pRB in mam-
mals [104], leaving in question how pRB uses the LXCXE
binding cleft? The fact that mice with LXCXE cleft muta-
tions are viable creates a perplexing contradiction since its
maintenance creates susceptibility to the pathogenic
effects of DNA tumor viruses [105]. Since the LXCXE
binding cleft on pRB is one of the most well conserved fea-
tures of RB family proteins [38] it must have an important
function. Determining the cellular context where LXCXE
interactions with pRB are essential is the first step to
understanding this aspect of pRB function. Further explo-
ration of phenotypes in LXCXE binding cleft mutant mice
should guide this analysis. Identifying the exact LXCXE
dependent partners that cooperate with pRB remains a
daunting task. A true understanding of how pRB uses
LXCXE interactions will likely require some rationaliza-
tion of the many possible binding partners.
Induction of differentiation and transcriptional 
activation; is pRB a switch hitter?
In the preceding sections little effort has been made to dis-
criminate between cell cycle arrest and terminal differen-
tiation. Both involve a block in cell proliferation;
however, terminal differentiation also includes a signifi-
cant change in gene expression patterns as these cells take
on a specialized function. In addition to participating in
cell cycle exit, pRB has been proposed to augment expres-
sion of cell type specific genes during differentiation
[12,13]. In this way pRB can aid in transcriptional repres-
sion as well as activation, depending on the cellular con-
text. This section of the review will focus on the
mechanisms that pRB participates in to facilitate tran-
scription in differentiation.
The activity of transcription factors that induce differenti-
ation can be augmented by pRB. These include MyoD,
CBFA1/RUNX2, C/EBPs, NF-IL6, Pax transcription fac-
tors, and nuclear hormone receptors [14,16,106-112]. In
addition, pRB dependent inhibition of proteins like EID-
1, Id2, and RBP2 has also been shown to activate tran-
scription during differentiation [85,86,93,113]. So how
does pRB induce differentiation? From a structure-func-
tion perspective the best evidence for pRB's role in differ-
entiation has come from a synthetic mutant pRB called
∆663 that substitutes five amino acids in the pRB pocket
starting at codon 663 to the peptide sequence NAIRS. This
protein is defective for E2F binding, transcriptional
repression, and induction of a G1 arrest. However, expres-
sion of this mutant induces markers of both muscle and
bone differentiation [47]. It has also been reported that
mutations in the LXCXE cleft of pRB prevent it from fully
activating MyoD dependent transcription during myogen-
esis [114]. Because of the structural component underly-
ing the data on pRB's role in muscle and bone
differentiation, these paradigms will be discussed further.
In the case of muscle, pRB is necessary for MyoD to maxi-
mally induce late markers of differentiation [15,106]. Pre-
cisely how pRB augments MyoD is not known but it seems
to involve influencing phosphorylation of MEF2C that is
necessary for maximal transcription of late markers [115].
In the case of bone differentiation, direct interaction
between pRB and HES1 with RUNX2/CBFA1 induces
DNA binding and enhanced transcriptional activation of
bone specific transcriptional targets [116]. Conversely,
induction of muscle or bone differentiation can be aided
by pRB's ability to antagonize HDAC1, EID-1, and RBP2
in transcriptional regulation. HDAC1 is able to inhibit
MyoD in cycling cells and upon induction of differentia-
tion pRB titrates HDAC1 away from MyoD allowing it to
activate transcription. Similarly, EID-1 can inhibit p300/
CBP acetylase activity that is necessary for MyoD to acti-
vate transcription. At the onset of differentiation, pRB
binds to EID-1 and targets it for degradation thereby
allowing MyoD to recruit p300 to stimulate transcription
of muscle specific genes [85,86]. In a similar manner, pRB
has been proposed to interact with RBP2 and remove it
from promoters where it inhibits transcriptional activa-
tion through its H3-K4 demethylase activity [93,117]. In
assays of CBFA1/RUNX2 dependent activation, pRB's
stimulatory effect is abrogated by siRNA depletion of
RBP2 [93]. Likewise, MyoD's inability to stimulate differ-
entiation in pRB deficient fibroblasts can be rescued by
simultaneous depletion of RBP2 [93]. These data strongly
suggests that RBP2, HDAC1, and EID-1 along with pRB
play critical roles in differentiation through antagonism.
These mechanisms offer insight into how pRB can func-
tion in aspects of differentiation beyond a mere G1 arrest.Cell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
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However, many questions remain regarding pRB's role in
differentiation. Since the work highlighted above does not
reveal much common ground between these different
mechanisms, but a single mutant (∆663) is capable of
inducing many of them, does pRB have one type of pro-
tein-protein interaction just for differentiation? Or are
there many, subtle activation mechanisms where no one
mechanism is essential? If the second possibility is true,
then does this imply that pRB is really just a cell cycle reg-
ulator and its role in differentiation is indirect? When con-
sidering this possibility it is important to remember that
CKI proteins p16 and p21 can block proliferation, but can
not enhance transcription by MyoD [15]. Only pRB has
this dual ability, suggesting that it must have additional
activities in differentiation beyond G1 arrest.
In order to move forward and come to a firm conclusion
about how pRB works in differentiation, new structure-
function data is imperative to define which interaction
surfaces are essential. The ∆663 mutant is defective for
E2F binding as well as contact with LXCXE proteins sug-
gesting that neither of these is likely to be necessary for
transcriptional activation [47]. Curiously, each of
HDAC1, EID-1, and RBP2 are proposed to contact pRB
using an LXCXE motif [22,82,85,86]. This apparent con-
tradiction raises the question of whether LXCXE interac-
tions are really necessary in differentiation? Rb deficient
embryos that are rescued by a normal placenta can
develop to birth where they die due to defects in myogen-
esis [118], revealing a place in development where pRB
plays an essential function in this differentiation para-
digm. Isaac et al. report that homozygous mutation of the
LXCXE binding cleft results in a viable mouse [99], indi-
cating that LXCXE interactions with pRB are not be essen-
tial for muscle development. However, Benevolenskaya et
al. have shown that RBP2 can interact with the R661W
mutant of pRB and mutation of the LXCXE motif on RBP2
has only a minimal effect on the interaction with pRB
[93]. This suggests that possession of an LXCXE motif
does not mean that it is essential for mediating an interac-
tion with pRB. In short, structure-function analysis of
pRB's role in differentiation has wet our appetite about
what it may do, but has left us unsure of how it actually
participates.
Future work in this area would be greatly aided by a class
of pRB mutants that can block proliferation, but not
induce differentiation, rather than the reciprocal proper-
ties that have already been reported. This type of mutant
will focus our attention on which contacts are essential for
pRB dependent transcriptional activation.
Regulation by post-translational modifications, 
just an on-off switch or are there different 
settings?
The retinoblastoma protein is a target for many post-
translational modifications. The most extensively studied
aspect of pRB regulation is phosphorylation [4], however,
it can be acetylated [119] and sumoylated [120] as well. In
addition, apoptotic signaling can modify pRB function by
proteolytic cleavage [121].
Regulation of pRB by phosphorylation was first observed
as a mobility shift in SDS-PAGE where pRB is faster
migrating in G1 phase cells and slower migrating in S, G2,
and M-phase [122-125]. This behavior gave rise to the
terms hypophosphorylated (pRB) and hyperphosphor-
ylated (ppRB) when referring to these bands in western
blots. Binding assays to study pRB interactions with E2Fs,
chromatin regulators, and other binding partners have
revealed an almost uniform preference for binding to the
hypophosphorylated form of pRB [4,24]. This indicates
that pRB binds to its interacting partners in G1 when it is
underphosphorylated implicating this as the active form.
Phosphorylation at the beginning of S-phase then pre-
vents pRB from interacting with other proteins until the
end of mitosis when it is dephosphorylated [126]. Based
on this data, phosphorylation offers a relatively clear on-
off mechanism for pRB regulation and this has been dis-
cussed in great depth in many previous reviews [3-7,18].
However, a considerable number of experiments raise the
question of how closely is this golden rule actually fol-
lowed?
The earliest studies of pRB phosphorylation have used cell
synchronization procedures to enrich for cells containing
active pRB in G1 and inactive ppRB from the other phases
[55,125]. The presence of pRB/E2F complexes in other
phases of the cell cycle has often been described as a tech-
nical artifact of the synchronization procedure, or the lag
between new synthesis of pRB and its phosphorylation. A
number of recent reports have demonstrated by ChIP that
pRB/E2F complexes can be detected on DNA in S-phase
cells [127,128]. Furthermore, analysis of RBF/dE2F com-
plexes from fruit flies indicates that some are resistant to
inactivation by cyclin/Cdks and these repress transcrip-
tion at all stages of the cell cycle as revealed by synchro-
nous cell divisions in the developing eye disc [129,130].
Taken together this indicates there are circumstances
where pRB family proteins are resistant to inactivation by
cyclin/Cdks despite being exposed to high levels of their
activity.
Phospho-peptide maps have suggested as many as 21
phosphorylation sites on pRB [131,132]. Through
sequence analysis, human pRB contains as many as 16
potential cyclin/Cdk phosphorylation sites containing theCell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
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S/T-P consensus [31]. These phosphorylation sites are
located in three general areas of the pRB open reading
frame, the N-terminus near the beginning of the pocket
domain, the spacer region, and the C-terminal domain
just after the small pocket (Figure 5). In G1, cyclin D/
Cdk4 complexes make use of a Cdk4 binding site in the
extreme C-terminus of pRB that is required for efficient
phosphorylation [133]. Ablation of all three D-cyclin
genes reduces phosphorylation on residues 249, 252, 807,
811, and 826 of pRB suggesting that they are primarily the
targets of D associated kinases [134]. Cyclin E/Cdk2
becomes active near the G1-S boundary and uses an inter-
action motif called RxL or Cy to recognize pRB and phos-
phorylate the remaining sites [135-137]. There are a
number of potential RxL motifs in the C-terminus of pRB,
but mutagenesis indicates that two adjacent motifs that
begin with lysine residues 870 and 873 are the most
important [135]. These experiments reveal a concerted
mechanism in which D and E cyclin/Cdk complexes bind
to pRB at discrete locations in the C-terminus and phos-
phorylate it at other locations. A number of reports have
suggested that the C-terminus of pRB is largely disordered
and flexible [38]. This allows substrate recognition
through binding while flexibility ensures access to phos-
pho-acceptor sites.
Using mutagenesis 11 of the possible 16 Cdk phosphor-
ylation sites have been substituted to alanine to prevent
inactivation of pRB [31-33]. Experiments using these con-
structs have revealed that this non-phosphorylatable form
of pRB can block cell proliferation in fibroblasts and
tumor derived cell lines [32,33,138]. Examination of pRB
mutants that have only a subset of these substitutions
reveals that there is no single phosphorylation site that
plays a critical role in the inactivation of E2F binding to
pRB [31,32,139]. However, interactions at the LXCXE
binding cleft can be regulated by a subset of phosphoryla-
tion sites in the C-terminal region of pRB [140,141]. Curi-
ously, arrest of Saos-2 cells with non-phosphorylatable
pRB can be bypassed by cyclin/Cdks without phosphor-
ylating pRB [138]. Thus, phosphorylation of pRB to con-
trol advancement of the cell cycle may be dispensable. In
addition, expression of non-phosphorylatable pRB in
mammary epithelia of transgenic mice initially causes
slowed proliferation during development, but eventually
ductal infiltration of the fat pad catches up and exhibits
hyperplasia and in some cases carcinogenesis [142]. The
authors of this study argue that non-phosphorylatable
pRB would also remain active for the inhibition of E2F
induced apoptosis and this could explain its oncogenic
properties. Regardless of the interpretation, it is clear from
these transgenic studies that phosphorylation of pRB is
not ubiquitously required for cell division to occur.
In addition to post-translational modifications that occur
in response to mitogenic signals, pRB is also modified in
response to DNA damage. Acetylation of lysines 873 and
874, as well as phosphorylation of serine 612 occurs rap-
idly in response to double strand DNA breaks [143,144].
The immediate implication of these findings is that post-
translational modifications on pRB can occur under cir-
cumstances other than proliferative control. In fact, DNA
damage activates G1 and S-phase arrest mechanisms that
dephosphorylate ppRB at cyclin/Cdk sites [128,145,146].
This implies that modifications added to pRB following
DNA damage result in a gain in function. The exact mech-
anism of action that these modifications initiate is not
clear. Phosphorylation of Ser612 has been reported to
enhance binding to E2Fs as an anti-apoptotic mechanism
[144] while acetylation of 873, 874 has been suggested to
release E2Fs to induce cell death [143]. To further add to
the confusion of how acetylation of pRB regulates its func-
tion, Nguyen and co-workers have shown that pRB
becomes acetylated during muscle differentiation [147].
Using a non-acetylatable mutant where lysines 873 and
874 are changed to arginines, they demonstrated that this
mutation leaves E2F transcriptional regulation intact.
Interestingly, the resulting muscle cells are susceptible to
re-entry into S-phase when stimulated by serum suggest-
ing that acetylation is necessary for pRB to enforce perma-
nent cell cycle exit. Clearly more work is needed to define
the role of pRB 'activation' in differentiation or following
DNA damage, but these studies illustrate that there is
Post-translational modifications of pRB Figure 5
Post-translational modifications of pRB. The open 
reading frame of pRB is depicted with the A and B regions of 
the pocket indicated. Cyclin/Cdk phosphorylation sites that 
have been investigated by mutagenesis are shown as are sites 
of phosphorylation following DNA damage. The location of 
acetylated and sumoylated lysines are indicated. Arrows indi-
cate the approximate location of Cdk4 and cyclin E binding 
sites that are needed for optimal phosphorylation of pRB. 
Caspase cleavage of pRB occurs on the C-terminal side of 
aspartate 886, removing amino acids 887 to 928.
AB 1 928
Phosphorylation-
DNA Damage:
Cyclin/Cdk:
Sumoylation:
Acetylation:
Ser 780, Ser 788, Ser 795,
Ser 807, Ser 811, Thr 821,
Thr 826
Ser 612
Ser 608 Thr252 Thr356
Lys 873,
Lys 874
Lys 720
Caspase Cleavage:
Cyclin/Cdk Binding: Cdk4 Cyclin E/A
Asp 886
ABCell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
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more to the regulation of pRB than a simple on-off mech-
anism at the G1-S boundary. One implication of acetyla-
tion of lysines 873 and 874 is that there may be a
hierarchy of pRB regulation where acetylation blocks
phosphorylation because the Cy motifs at this same posi-
tion are no longer recognized by cyclin E/Cdk2. This
could be advantageous in differentiation and DNA dam-
age because it would prevent promiscuous phosphoryla-
tion of pRB and ensure cell cycle arrest.
The most recently discovered modification of pRB is
sumoylation. Sumoylation is a ubiquitin like modifica-
tion that has recently been implicated in numerous bio-
logical functions, including the induction of senescence
[148]. The retinoblastoma protein has been reported to be
sumoylated in the small pocket near the LXCXE binding
cleft at lysine 720 [120]. The exact mechanistic conse-
quence of modifying pRB with sumo is not fully under-
stood, however, it has been proposed to compete with
proteins that bind to the LXCXE cleft. In other studies of
sumoylation, the overall effect of this modification on
p53 and RBP1 is an induction of senescence [149,150].
Whether sumoylation of pRB plays a role in the induction
of senescence is not known, but the pRB LXCXE binding
cleft has been proposed to interact with chromatin regula-
tors to establish repressive heterochromatin as part of a
permanent arrest [151]. This raises the question of
whether HP1 and other chromatin regulators can contact
pRB if sumo is interfering with access to this surface.
Tumor necrosis factor alpha (TNF-α) stimulates inflam-
mation and apoptosis [152]. It signals to activate so called
'initiator' caspases that cleave substrates as part of a sign-
aling cascade that ultimately leads to the activation of
'effector' caspases that ultimately kill the cell. Caspase
cleavage of pRB occurs at an intermediate step of TNF-α
signaling and results in the irreversible removal of the C-
terminal 42 amino acids [153,154]. This is defined as an
intermediate step in cell death because expression of a cas-
pase resistant mutant of pRB inhibits progression of sign-
aling and the effector caspases are never activated
[153,154]. Using a knock-in mouse model where the
DEADG recognition sequence in pRB is changed to
DEAAE (called pRB-MI), Chau et al. showed that intesti-
nal epithelia are uniquely resistant to TNF-α mediated cell
death [155]. Furthermore, crossing the pRB-MI mice to
p53-/- mice results in frequent colonic adenomas that are
rare in p53-/- mice. This work suggests that pRB is a critical
target in apoptotic induction by TNF-α and disruption of
this pathway in the intestine allows damaged cells to sur-
vive and begin to form tumors [156]. Unfortunately, the
mechanistic details of how pRB is regulated by proteolysis
are less well understood. Two possibilities are that cleav-
age eliminates binding to a pro-apoptotic factor that pRB
normally sequesters and its release allows cell death can to
ensue [154,155], alternatively removal of the last 42
amino acids destabilizes pRB so that it's expression is
eventually lost [153]. In this way cells would effectively
behave as if they were pRB deficient and E2F1 would be
liberated to kill cells. Given that TNF-α can induce cell
death without the need for new protein expression, the
former possibility seems more likely although there
remains much to be done to understand this mechanism
[155].
To summarize our present knowledge of post-transla-
tional regulation of pRB, most attention has been focused
on phosphorylation and this modification has been
shown to block pRB's growth inhibitory properties.
Despite the preponderance of evidence for negative regu-
lation of pRB by phosphorylation, it is clear that excep-
tions exist to this regulatory mechanism. Perhaps other
regulatory modifications can 'mark' pRB to retain func-
tion in the face of cyclin/Cdks as described above, or inac-
tivate it without phosphorylation. The answer to how pRB
regulation is impacted by multiple signaling pathways
will need to await further investigation. Never the less,
these different types of modifications are revealing further
complexity to an already multi-functional protein.
Conclusion
A common theme in this review is that a large number of
proteins contact a relatively small region of pRB. Muta-
tions that affect the pocket domain can simultaneously
disrupt many aspects of pRB and have made dissecting
interactions within this domain very difficult. Perhaps the
reason why a vast majority of tumor-derived alleles of RB-
1 eliminate the pocket domain completely [8] is because
they represent the easiest way to disrupt everything that
pRB does. Never the less, with a multi-functional protein
like pRB where so much is mediated by just the large
pocket domain, it is even more important to define how
different interacting proteins can act together with it to
control cell growth. Without this level of understanding
we will never be able to say how pRB really works.
Despite the challenges of a structure-function based
approach to pRB, discussing its function based on differ-
ent protein interaction sites, or structural domains, as
described above readily covers most aspects of pRB's
known role in proliferative control and cancer. In nearly
each case the use of mutants with defined defects reveals
that the prevailing view of pRB function is part of how it
works but unlikely to be the whole explanation. These
structure-function approaches to study pRB have revealed
many unexplained activities and highlight areas for fur-
ther investigation. Just how important are these unex-
plored areas? A recent paper by Binne et al. shows that
without Cdh1, pRB has almost no ability to induce a G1
cell cycle arrest [70]. Likewise, Sellers et al. have shown aCell Division 2007, 2:26 http://www.celldiv.com/content/2/1/26
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dramatic separation of proliferative and differentiation
activities [47]. Thus, a number of these emerging areas are
likely quite central to pRB function but are simply less
well understood.
Structure-function approaches offer a reliable means to
examine how proteins interact with one another to carry
out various cellular processes. Combined with genetic
analysis that defines sufficiency and necessity, the purpose
of individual protein-protein interactions can be very
effectively defined. Despite using this approach, we still
struggle to draw firm conclusions about what makes pRB
a tumor suppressor. The properties of the low-penetrance
allele R661W suggest that E2F interactions are an essential
component of this function. However, since this allele is
only partially penetrant, and some carriers of this muta-
tion can live cancer free [157], is it telling us that E2F
binding is only a small part of tumor suppression by pRB?
Does this implicate Cdh1/Skp2 binding in tumor suppres-
sion because it is part of the proliferative control mecha-
nism that functions in the absence of E2F control in the
R661W mutant? Or should we exclude Cdh1/Skp2 inter-
actions because they are not deficient in R661W? Clearly
more data on tumor predisposition caused by partially
defective pRB molecules is essential to draw firm conclu-
sions about this crucial question. Since there are a limited
number of tumor derived mutations to choose from, gen-
erating more synthetic alleles with discrete defects is likely
the only way forward. For example, if gene-targeted mice
carrying the LXCXE cleft mutation turn out to be tumor
prone, then we would conclude that LXCXE interactions
are part of pRB's tumor suppressor function. This would
undoubtedly motivate more effort to identify precisely
how pRB uses this type of interaction compared with
another binding site that is excluded by a similar tumor
incidence study.
This type of systematic approach to investigating pRB
tumor suppression could be brought to bear on many pRB
interactors and binding sites. However, as lists like that in
Table 1 reveal, pRB interacting proteins are numerous
[24]. A potential opportunity to better focus our efforts on
what makes pRB a tumor suppressor may also come from
comparisons with the related pocket proteins p107 and
p130. As stated earlier, these molecules share extensive
similarity with pRB in the pocket domain, yet on their
own neither appears to meet the genetic definition of a
tumor suppressor gene. Focusing on proteins that interact
with pRB and not p107 and p130 could help to guide our
selection of interactors that are most relevant in cancer. By
this way of thinking, a complex like APCcdh1 would hold
considerable appeal because it selectively binds pRB over
p107 and p130 even in in vitro binding assays [70]. Alter-
natively, the dREAM complex that we now know only
contacts p130 in vivo [104] would be a less appealing can-
didate to cooperate with pRB in tumor suppression.
Advancing our understanding of pRB function in this
most crucial of questions will clearly require multiple
approaches. The investigation of endogenous pRB protein
complex composition, combined with structure-function
analysis of discrete mutant alleles of the RB-1 gene, offers
a logical means to separate pRB function into distinct
parts to define its role in cancer.
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